Loading...
•
Mar 31, 2021
McKesson Q4 2021 Earnings Report
Reported fourth-quarter and full-year results for fiscal year 2021.
Key Takeaways
McKesson's fourth-quarter revenues increased by 1% to $59.1 billion, driven by market growth and higher volumes from retail national account customers in the U.S. Pharmaceutical segment. The company's adjusted EPS increased by 18% to $5.05, primarily driven by COVID-19 vaccine distribution and kitting programs.
Fourth-quarter total revenues of $59.1 billion increased 1%.
Full-year total revenues of $238.2 billion increased 3%.
Fourth-quarter Adjusted Earnings per diluted share of $5.05 increased 18%.
Full-year Free Cash Flow of $3.9 billion.
McKesson
McKesson
McKesson Revenue by Segment
Revenue by Segment
U.S. Pharmaceutical Revenue
CapyFin.comPrescription Technology Solutions Revenue
CapyFin.comMedical-Surgical Solutions Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
McKesson expects full-year fiscal 2022 Adjusted Earnings per diluted share of $18.85 to $19.45, which reflects Adjusted Operating Profit growth in all segments coupled with disciplined, efficient capital deployment, including approximately $2 billion of share repurchases.
Positive Outlook
- Adjusted Operating Profit growth in all segments
- Disciplined, efficient capital deployment
- Approximately $2 billion of share repurchases
- Adjusted Earnings per diluted share guidance range of $18.85 to $19.45
- 3% to 6% growth in Revenues
Challenges Ahead
- Guidance assumes $0.50 to $0.70 of Adjusted Earnings per diluted share related to the U.S. government’s COVID-19 vaccine distribution and kitting programs
- Risks and uncertainties such as those described in the Cautionary Statements
- Changes in pricing and reimbursement models
- Changes or disruptions in product supply
- Difficulties in sourcing products and changes in pricing due to the effects of the COVID-19 pandemic on supply chains
Revenue & Expenses
Visualization of income flow from segment revenue to net income